the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.

Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD

NCT07194863 ·Status: NOT_YET_RECRUITING

Target of Suv420h1/2 in Hepatocytes

NCT06332677 ·Status: RECRUITING ·Phase: NA

A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

NCT03950882 ·Status: COMPLETED ·Phase: PHASE1

Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study

NCT02457637 ·Status: COMPLETED

A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis

NCT00492700 ·Status: COMPLETED ·Phase: PHASE2

Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)

NCT00681733 ·Status: UNKNOWN ·Phase: NA

Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients

NCT05465642 ·Status: UNKNOWN

Study of [14C]CS0159 in China Healthy Subjects

NCT06098027 ·Status: COMPLETED ·Phase: PHASE1

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

NCT06024408 ·Status: COMPLETED ·Phase: PHASE1

The Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis

NCT02231333 ·Status: COMPLETED ·Phase: NA

Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease

NCT02217345 ·Status: COMPLETED ·Phase: PHASE2

Integrated Approaches for Identifying Molecular Targets in Liver Disease

NCT03915002 ·Status: COMPLETED

Plasma Proteomics Study of End-Stage Liver Disease Patients Based on Olink Technology

NCT06865898 ·Status: ACTIVE_NOT_RECRUITING

Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

NCT04454463 ·Status: COMPLETED

The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis

NCT01068444 ·Status: COMPLETED ·Phase: PHASE2

Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease

NCT05419765 ·Status: COMPLETED

A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar

NCT06193629 ·Status: RECRUITING ·Phase: NA

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

NCT03763877 ·Status: COMPLETED ·Phase: PHASE2

CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)

NCT05896137 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Clinical Trial of Pentoxifylline in Patient With Cirrhosis

NCT00162552 ·Status: COMPLETED ·Phase: PHASE3

Ketotifen in Non-Alcoholic Fatty Liver Disease Patients

NCT05616442 ·Status: COMPLETED ·Phase: PHASE4

Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease

NCT01963845 ·Status: COMPLETED ·Phase: PHASE2

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05648214 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)

NCT05129904 ·Status: UNKNOWN

Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development

NCT03780673 ·Status: COMPLETED ·Phase: PHASE2/PHASE3